DLEU1 Antibody

What is DLEU1 and why is it significant in cancer research?

DLEU1 is a long non-coding RNA encoded by a gene localized in chromosome 13q14.3, a region frequently deleted in hematological malignancies . Despite its location in a commonly deleted region suggesting a potential tumor suppressor role, recent evidence demonstrates that DLEU1 exhibits oncogenic properties . It is significantly upregulated in multiple cancer types including esophageal squamous cell carcinoma (ESCC), cholangiocarcinoma (CCA), and breast cancer, where its overexpression correlates with poor prognosis . DLEU1's significance lies in its involvement in various cancer-promoting mechanisms, including apoptosis inhibition, chemoresistance enhancement, and tumor stemness maintenance, making it an important research target for potential therapeutic interventions .

What types of DLEU1 antibodies are available for research applications?

Based on current research resources, several types of DLEU1 antibodies are available for experimental applications, including:

• Polyclonal antibodies targeting specific amino acid regions (e.g., AA 1-78)

• Monoclonal antibodies (e.g., clone 2C2)

• Conjugated antibodies including:

  • HRP-conjugated antibodies for enhanced detection sensitivity

  • FITC-conjugated antibodies for fluorescence applications

  • Biotin-conjugated antibodies for streptavidin-based detection systems

These antibodies offer different specificities and applications depending on experimental needs, with reactivity primarily against human DLEU1 .

What are the common applications for DLEU1 antibodies in research?

DLEU1 antibodies are utilized in multiple experimental approaches:

• Immunohistochemistry (IHC): For detection of DLEU1 expression in tissue sections, commonly used with recommended dilutions of 1:20-1:200

• Immunofluorescence (IF): For subcellular localization studies with typical dilutions of 1:50-1:200

• ELISA: For quantitative detection of DLEU1 in research samples

• Western blotting: For protein expression analysis in cell and tissue lysates

• RNA immunoprecipitation: For studying RNA-protein interactions, as demonstrated in studies examining DLEU1's association with proteins such as DYNLL1

How is DLEU1 expression regulated in cancer cells?

Research has identified several regulatory mechanisms controlling DLEU1 expression in cancer:

• Epigenetic regulation: DLEU1 upregulation is partly facilitated by promoter hypomethylation in ESCC, suggesting epigenetic dysregulation contributes to its overexpression .

• Transcription factor-mediated regulation: In cholangiocarcinoma, the transcription factor YY1 has been identified as an upstream regulator of DLEU1. ChIP assays demonstrated that YY1 antibody significantly enriched E1 fragments of the DLEU1 promoter, and luciferase reporter assays confirmed YY1 activated wild-type E1 luciferase plasmid but not mutant E1 plasmid .

• Positive correlation with other cancer markers: YY1 expression shows positive correlation with DLEU1 expression in CCA tissues (r = 0.4482, p < 0.001), suggesting coordinated regulatory mechanisms .

What methodologies can detect subcellular localization of DLEU1?

Determining the subcellular localization of DLEU1 is crucial for understanding its function:

• Subcellular fractionation combined with qRT-PCR: Research has shown DLEU1 is principally expressed in the cytoplasm of cancer cells .

• Immunofluorescence using FITC-conjugated DLEU1 antibodies: These can be employed at dilutions of 1:50-1:200 to visualize DLEU1 distribution within cells .

• RNA-FISH (Fluorescence In Situ Hybridization): While not explicitly mentioned in the search results, this technique is commonly used for lncRNA localization studies and would complement antibody-based approaches.

• Co-localization studies: Research has demonstrated DLEU1's interaction with proteins like DYNLL1 and HIF-1α, suggesting methodological approaches combining DLEU1 antibodies with antibodies against these interaction partners can provide insights into functional subcellular compartmentalization .

How does DLEU1 expression correlate with clinical features in cancer patients?

DLEU1 expression shows significant correlations with several clinical parameters across different cancer types:

Additionally, DLEU1 expression was significantly upregulated in tumor tissues compared to adjacent normal tissues across multiple cancer types, as demonstrated by analyses of TCGA datasets and experimental validation .

What are the optimal experimental controls when using DLEU1 antibodies?

When designing experiments with DLEU1 antibodies, researchers should incorporate these critical controls:

• Antibody specificity controls:

  • Isotype control antibodies matching the DLEU1 antibody class (e.g., IgG for polyclonal antibodies)

  • DLEU1 knockdown cells to validate signal specificity

  • Peptide competition assays using the immunogen (e.g., recombinant Human Leukemia-associated protein 1 protein (1-78AA))

• Expression validation controls:

  • Parallel qRT-PCR to confirm DLEU1 RNA expression levels

  • Use of multiple DLEU1 antibodies targeting different epitopes

  • Comparison between normal and cancer tissues/cells with known DLEU1 expression differences

• Technical controls:

  • Secondary antibody-only controls to assess background

  • Positive controls using tissues/cells with confirmed DLEU1 expression

  • Negative controls using tissues/cells with confirmed low/no DLEU1 expression

How can DLEU1's interaction with protein partners be effectively studied?

Several methodological approaches have been validated for studying DLEU1's protein interactions:

• RNA pull-down assays: In vitro transcribed DLEU1 RNA (biotin-labeled) can be used to pull down associated proteins like DYNLL1. This approach has successfully identified DLEU1-DYNLL1 interaction and can be extended to mapping interaction domains using deletion mutants .

• RNA immunoprecipitation (RIP): Using antibodies against putative protein partners (e.g., anti-DYNLL1 antibody) followed by qRT-PCR analysis of DLEU1 in the immunoprecipitates .

• Co-immunoprecipitation (Co-IP): For studying protein-protein interactions in the DLEU1 interactome, such as between DYNLL1 and RNF114 .

• Deletion mutant analysis: Construction of DLEU1 deletion mutants (e.g., Del1 (1–1086 nt), Del2 (1–724 nt), etc.) can help map specific interaction domains .

• Proximity ligation assays: While not explicitly mentioned in the search results, this technique could provide spatial resolution of DLEU1-protein interactions in situ.

What knockdown and overexpression approaches are effective for DLEU1 functional studies?

Research has validated several genetic manipulation techniques for DLEU1:

• Knockdown approaches:

  • siRNA-mediated knockdown (e.g., si-DLEU1-1, si-DLEU1-2) with validated efficacy as confirmed by qRT-PCR

  • shRNA-mediated stable knockdown for long-term studies and in vivo experiments

• Overexpression approaches:

  • Plasmid-based overexpression (e.g., pcDNA3.1-DLEU1) for transient expression studies

  • Stable transfection with selection markers for long-term studies and in vivo models

• Validation metrics:

  • qRT-PCR to confirm expression changes

  • Functional readouts including proliferation assays, apoptosis assays, migration/invasion assays, and tumor sphere formation assays

How can DLEU1 antibodies be utilized to investigate its role in chemoresistance mechanisms?

DLEU1 has been implicated in chemoresistance across multiple cancer types. Research methodologies to investigate this include:

• Combination treatment approaches: DLEU1 knockdown or overexpression cells can be treated with chemotherapeutic agents (cisplatin, gemcitabine) in time-dependent and dose-dependent modes to assess survival differences using CCK-8 assays or similar viability metrics .

• In vivo chemosensitization studies: Xenograft models with DLEU1-manipulated cells followed by chemotherapy treatment can validate in vitro findings. Studies have shown that DLEU1 overexpression enhances resistance to cisplatin and gemcitabine in vivo, as measured by normalized tumor volumes and weights .

• Mechanistic investigation: DLEU1 antibodies can help elucidate the molecular interactions underlying chemoresistance, such as the DLEU1/DYNLL1/BCL2 axis in ESCC .

• Stem cell marker correlation: Using DLEU1 antibodies alongside antibodies against stem cell markers (SOX2, OCT4, Nanog, KLF4) can help understand relationships between DLEU1-mediated stemness and chemoresistance .

What methodological approaches can resolve contradictory findings about DLEU1's role as tumor suppressor versus oncogene?

The literature contains an apparent contradiction: DLEU1's genomic location in a commonly deleted region (13q14.3) suggests a tumor suppressor role, yet functional studies demonstrate oncogenic properties . To resolve this paradox:

• Tissue-specific expression analysis: Comprehensive profiling of DLEU1 expression across different tissue types using antibody-based approaches (IHC, western blotting) and RNA-based methods (qRT-PCR, RNA-seq) .

• Genetic context evaluation: Investigating whether DLEU1 functions differently depending on the genetic background of cells, potentially through CRISPR-engineered isogenic cell lines with various genetic alterations.

• Structural and functional domain mapping: Using deletion mutants and domain-specific antibodies to determine if different regions of DLEU1 mediate opposing functions .

• Interactome characterization: Comprehensive identification of DLEU1-interacting proteins across different cellular contexts using techniques like RNA pull-down followed by mass spectrometry .

• Epigenetic regulation analysis: Investigating whether the functional outcome of DLEU1 expression depends on epigenetic context, potentially through combined methylation analysis and functional studies .

How can DLEU1 antibodies help elucidate its role in tumor stemness and metastasis?

DLEU1 has been implicated in tumor stemness maintenance and metastasis promotion:

• Tumor spheroid formation assays: DLEU1 knockdown or overexpression affects spheroid formation capacity, which can be quantified and correlated with DLEU1 levels using antibody-based detection methods .

• Stem cell marker co-expression studies: IHC or immunofluorescence co-staining of DLEU1 with stem cell markers (SOX2, OCT4, Nanog, KLF4) in tissue samples and experimental models can reveal correlations and potential regulatory relationships .

• EMT process investigation: DLEU1 has been shown to boost tumor EMT (epithelial-mesenchymal transition), a key process in metastasis. Antibody-based detection of DLEU1 alongside EMT markers can help understand this relationship .

• In vivo metastasis models: Combined with fluorescent tagging or antibody-based detection methods, researchers can track DLEU1-manipulated cells during the metastatic process in animal models .

How might DLEU1 antibodies facilitate development of therapeutic targeting strategies?

DLEU1's involvement in multiple oncogenic processes makes it a potential therapeutic target:

• Target validation studies: DLEU1 antibodies can help validate knockdown efficiency and specificity of emerging therapeutic approaches like antisense oligonucleotides or siRNAs targeting DLEU1.

• Combination therapy assessment: Studies have shown that targeting DLEU1 sensitizes cancer cells to chemotherapeutic agents like cisplatin . Antibody-based detection of DLEU1 can help optimize such combination approaches.

• Biomarker development: Given DLEU1's correlation with prognosis and chemoresistance, antibody-based detection methods could be developed into clinical assays for patient stratification .

• Therapeutic resistance monitoring: DLEU1 antibodies could help monitor dynamic changes in DLEU1 expression during treatment, potentially identifying resistance mechanisms.

What experimental considerations are important when studying DLEU1's interaction with the hypoxia pathway?

Research has identified interaction between DLEU1 and HIF-1α in breast cancer :

• Hypoxia condition standardization: When studying DLEU1's relationship with hypoxia pathways, researchers should standardize hypoxic conditions (typically 1% O2) and duration.

• Co-immunoprecipitation approaches: To validate DLEU1's interaction with HIF-1α, techniques such as RNA-immunoprecipitation followed by qRT-PCR or western blotting should be employed.

• Transcriptional co-activation assessment: DLEU1 has been shown to act as a coactivator for HIF-1α in activating CKAP2 transcription. Chromatin immunoprecipitation (ChIP) assays with antibodies against HIF-1α, combined with DLEU1 manipulation, can help elucidate this mechanism .

• Downstream pathway analysis: Studying activation of ERK and STAT3 signaling downstream of the DLEU1/HIF-1α/CKAP2 axis requires careful selection of activation-specific antibodies and appropriate positive controls .

What factors should be considered when comparing DLEU1 expression across different cancer types?

When conducting comparative oncology studies involving DLEU1:

• Antibody consistency: Using the same antibody clone and detection protocol across different cancer types is essential for valid comparisons.

• Technical normalization: Standardizing immunohistochemistry scoring systems or quantitative protein/RNA detection methods across samples.

• Control tissue selection: Including appropriate normal tissue controls matched to each cancer type.

• Isoform specificity: Ensuring antibodies detect relevant isoforms that may be differentially expressed across cancer types.

• Multi-modal validation: Confirming antibody-based findings with orthogonal methods like qRT-PCR or RNA-seq data from resources like TCGA .